Preterm premature rupture of membranes (PPROM) effects approximately 3% of all pregnancies in the United States. [@JR190001-1] Pregnancies complicated by PPROM pose maternal risks including complications from chorioamnionitis, postpartum infections, and placental abruption, while their neonates face complications related to preterm birth including respiratory distress, necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), sepsis, and death. Additionally, fetuses exposed to intrauterine inflammation in PPROM have an increased risk of cerebral palsy. [@JR190001-2]

Antibiotics in PPROM reduce neonatal morbidity from sepsis, pneumonia, respiratory distress, and necrotizing enterocolitis. [@JR190001-3] [@JR190001-4] [@JR190001-5] [@JR190001-6] [@JR190001-7] Additionally, antibiotics prolong pregnancy latency and reduce maternal infectious morbidity from chorioamnionitis. [@JR190001-3] [@JR190001-5] [@JR190001-7] Given the body of literature on the benefits of antibiotic use in PPROM, the standard of care is a 7-day course of a penicillin (PCN) and macrolide for all women with this complication. [@JR190001-3]

One poorly understood caveat to this is the appropriate management strategy of women with PCN allergy, a common drug class allergy. PCN allergy is reported in up to 8% of individuals accessing care in the United States. [@JR190001-8] Although the majority of patients with a self-reported PCN allergy do not have a true allergy, [@JR190001-9] physicians may be reticent to administer a *β* -lactam antibiotic in this setting. No consistent recommendations regarding the appropriate antibiotic regimen to use in cases of PPROM in a patient with a PCN allergy exist. Also, some physicians may prefer non- *β* -lactam regimens for management of PPROM. However, data regarding the impact of alternative antibiotic regimen on neonatal morbidity and mortality as well as maternal infectious morbidity are unavailable. The objective of this study was to assess the impact of a non- *β* -lactam antibiotic regimen in expectant management of PPROM on neonatal morbidity and mortality. Additionally, we sought to describe impact of non- *β* -lactam antibiotic regimen on pregnancy latency and maternal infectious outcomes.

Methods
=======

This study is a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal--Fetal Medicine Units Network, beneficial effects of antenatal magnesium sulfate (BEAM) randomized, placebo controlled, and multicenter trial of antenatal magnesium sulfate for the prevention of cerebral palsy. [@JR190001-10] Duke University institutional review board determined the study to be exempt under protocol Pro00065517. We included singleton, nonanomalous pregnancies complicated by PPROM at or beyond 24 ^0/7^ weeks of gestation and delivery at less than 35 ^0/7^ weeks. The gestational age of 35 weeks was selected to minimize exclusion of women with PPROM who were induced starting at 34 weeks. We excluded multiple gestations, pregnancies complicated by chromosomal abnormalities, pregnancies where no antibiotics were administered, and those subjects with a missing date or time of rupture or delivery.

Women receiving the gold standard antibiotic regimen *β* -lactam and macrolide were compared with women receiving a non- *β* -lactam and macrolide regimen. PCN and cephalosporin antibiotic regimens were both included in the *β* -lactam group given their similar mechanism of action and similar hypersensitivity response. The primary outcome was a neonatal composite of severe necrotizing enterocolitis (NEC; defined as grade 2 or 3), severe intraventricular hemorrhage (defined as grade 4), periventricular leukomalacia (PVL), bronchopulmonary dysplasia (BPD), neonatal death prior to hospital discharge, sepsis, and cerebral palsy. Our secondary outcomes included all the components of the composite, pregnancy latency, and maternal endometritis and chorioamnionitis. Pregnancy latency was defined as the interval of time in days from membrane rupture to delivery.

The characteristics and outcomes of subjects receiving the different antibiotic regimens were compared using Kruskal--Wallis, Chi-squared or Fisher\'s exact test as appropriate. Multivariable logistic regression models for the outcomes of interest were then developed to estimate the true effect of the *β* -lactam and macrolide versus non- *β* -lactam antibiotic regimen. Covariates in the regression model included those significant in the bivariate analysis and those with known clinical associations to the outcome of interest. Backward stepwise regression was used with covariates with *p*  \< 0.20 were retained in final models. Variables in original model for neonatal composite included maternal age, marital status, maternal drug use, maternal tobacco use, mode of delivery, neonatal gender, neonatal birth weight, gestational age at birth, neonatal magnesium exposure, corticosteroids, group B streptococcus status, chorioamnionitis, and diabetes. The same statistical analysis was performed for the secondary analysis. STATA 13.1 (StataCorp, College Station, TX) was used to perform all analyses.

Results
=======

Of 2,444 pregnancies identified in the original BEAM trial, 949 women were included in the primary analysis ( [Fig. 1](#FI190001-1){ref-type="fig"} ); 821 (86.5%) patients received a *β* -lactam and macrolide and 128 (13.5%) received a non- *β* -lactam and macrolide. Within the non- *β* -lactam and macrolide group, 82 of the 128 women (64.1%) received clindamycin. Compared with women who received the *β* -lactam and macrolide antibiotic regimen, women who received the non- *β* -lactam and macrolide were older ( *p*  = 0.03), more likely to be Caucasian ( *p*  \< 0.01), married ( *p*  \< 0.01), and less likely to use illicit drugs ( *p*  = 0.01; [Table1](#TB190001-1){ref-type="table"} ). No differences in receipt of magnesium, corticosteroids, or tocolytics were noted ( [Table 2](#TB190001-2){ref-type="table"} ). Women receiving the gold standard antibiotic regimen had membrane rupture at a later median gestational age, 28.3 (IQR \[interquartile range\]: 26.3--30.3) weeks versus 27.3 (IQR: 25.3--30.0) weeks ( *p*  = 0.03). However, no differences in rates of spontaneous labor, Cesarean delivery, gestational age at delivery, birth weight, gender of newborn, or 5 minute Apgar\'s score between groups were noted ( [Table 2](#TB190001-2){ref-type="table"} ).

###### Demographic data of women receiving a *β* -lactam and macrolide compared with a non- *β* -lactam regimen after preterm premature rupture of membranes

  ---------------------------------------------------------------------------------------------
                                  *β* -Lactam and macrolide\   Non- *β* -lactam\   *p* -Value
                                  regimen\                     regimen\            
                                  *n * = 821 (%)               *n*  = 128 (%)      
  ------------------------------- ---------------------------- ------------------- ------------
  Median age, (IQR)               26 (21, 31)                  27 (22, 33)         0.03

  Race                                                                             \< 0.01

  Caucasian                       442 (53.8)                   47 (36.7)           

  Black                           297 (36.2)                   69 (53.9)           

  Hispanic                        65 (7.9)                     11 (8.6)            

  Other                           17 (2.1)                     1 (0.8)             

  Hispanic                        65 (7.9)                     11 (8.6)            0.79

  High school education or less   586 (71.4)                   87 (68.0)           0.43

  Married                         331 (40.3)                   74 (57.8)           \< 0.01

  Obese (BMI \> 30)               258 (31.4)                   39 (30.5)           0.83

  Multiparous                     538 (65.5)                   89 (69.5)           0.37

  Prior PTB                       252 (30.7)                   30 (23.4)           0.10

  Smoking                         287 (35.0)                   42 (32.8)           0.64

  Drugs use                       120 (14.6)                   7 (5.5)             0.01

  GBS positive                    470 (57.3)                   78 (60.9)           0.43

  Diabetes                        39 (4.8)                     7 (5.5)             0.73

  Any prenatal care               752 (91.6)                   119 (93.0)          0.60
  ---------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; GBS, group B strep; IQR, interquartile range; BEAM, beneficial effects of antenatal magnesium sulfate; PCN, penicillin; PPROM, preterm premature rupture of membranes; PTB, preterm birth.

###### Delivery and neonatal characteristics of women receiving a *β* -lactam and macrolide compared with a non- *β* -lactam regimen after preterm premature rupture of membranes

  ----------------------------------------------------------------------------------------------------------------------
                                                          *β* -lactam and macrolide\   Non- *β* lactam\     *p* -Value
                                                          regimen\                     regimen\             
                                                          *n * = 821 (%)               *n * = 128 (%)       
  ------------------------------------------------------- ---------------------------- -------------------- ------------
  Median gestational age at membrane rupture, wk, (IQR)   28.3 (26.3, 30.3)            27.3 (25.3, 30.0)    0.03

  Any magnesium exposure                                  147 (17.9)                   27 (21.1)            0.39

  Corticosteroids                                         813 (99.0)                   125 (97.7)           0.18

  Tocolytic exposure                                      20 (2.4)                     0 (0.0)              0.07

  Exposure to clindamycin                                 0 (0.0)                      82 (64.1)            \< 0.01

  Spontaneous labor                                       434 (52.9)                   69 (53.9)            0.84

  Median gestational age at delivery, wk, (IQR)           30.1 (27.9, 31.7)            29.7 (27.2, 31.6)    0.08

  Cesarean delivery                                       306 (37.3)                   52 (40.6)            0.47

  Median birth weight, g, (IQR)                           1,395 (1,037, 1,730)         1,355 (989--1,731)   0.48

  Male infant                                             435 (53.0)                   60 (46.9)            0.20

  5-minute Apgar\'s score \< 7                            131 (16.0)                   23 (18.0)            0.57
  ----------------------------------------------------------------------------------------------------------------------

Abbreviation: IQR, interquartile range.
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The primary neonatal composite outcome occurred in 28.3% of the *β* -lactam and macrolide group and 35.2% of the non- *β* -lactam and macrolide group ( *p*  = 0.11). When the individual components of the neonatal composite were analyzed, with the exception of severe necrotizing enterocolitis, neonates receiving the *β* -lactam and macrolide group trended toward a reduction in adverse outcomes, with bronchopulmonary dysplasia reaching clinical significance ( *p*  = 0.03; [Table 3](#TB190001-3){ref-type="table"} ). With regards to severe necrotizing enterocolitis, the inverse was seen ( *p*  = 0.04). In adjusted analyses, no difference between groups for the neonatal composite (adjusted odds ratio \[AOR\] = 0.50; 95% confidence interval \[CI\]: 0.22--1.11) was found when adjusting for maternal age, race, maternal drug use, neonatal gender, gestational age at birth, birth weight, magnesium exposure, clindamycin exposure, and corticosteroids

###### Maternal and neonatal outcomes for women receiving a *β* -lactam and macrolide compared with a non- *β* -lactam regimen after preterm premature rupture of membranes

  --------------------------------------------------------------------------------------------------------------------
                                           *β* -lactam and macrolide\   Non- *β* -lactam and macrolide\   *p* -Value
                                           regimen\                     regimen\                          
                                           *n*  = 821 (%)               *n*  = 128 (%)                    
  ---------------------------------------- ---------------------------- --------------------------------- ------------
  Maternal                                                                                                

  Median latency until delivery, d (IQR)   6.9 (3.4, 13.5)              7.0 (3.3, 15.4)                   0.74

  Endometritis                             49 (6.0)                     12 (9.4)                          0.14

  Chorioamnionitis                         94 (11.5)                    18 (14.1)                         0.39

  Neonatal                                                                                                

  Composite                                232 (28.3)                   45 (35.2)                         0.11

  Sepsis                                   108 (13.3)                   24 (18.8)                         0.10

  Death in NICU                            29 (3.6)                     6 (4.7)                           0.53

  Severe IVH                               13 (1.6)                     3 (2.4)                           0.54

  PVL                                      12 (1.5)                     4 (3.2)                           0.18

  BPD                                      128 (15.7)                   30 (23.4)                         0.03

  Severe NEC                               38 (4.7)                     1 (0.8)                           0.04

  Any cerebral palsy                       29 (3.7)                     8 (6.5)                           0.14
  --------------------------------------------------------------------------------------------------------------------

Abbreviations: BPD, bronchopulmonary dysplasia; IQR, interquartile range; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; NICU, Neonatal intensive care unit; PVL, periventricular leukomalacia.

Regarding maternal outcomes, risk of chorioamnionitis and endometritis did not differ, nor did the median latency (6.9 days \[IQR: 3.4--13.5\] vs. 7.0 days \[IQR: 3.3--15.4\]; [Table 3](#TB190001-3){ref-type="table"} ). After controlling for confounders, the risk for chorioamnionitis remained nonsignificant ( [Table 4](#TB190001-4){ref-type="table"} ). However, women receiving the gold standard antibiotic regimen were less likely to get endometritis, (AOR = 0.35; 95% CI: 0.14--0.91).

###### Adjusted odds ratio of maternal and neonatal outcomes for women receiving a *β* -lactam and macrolide compared with a non- *β* -lactam regimen

                                                             Odds ratio   95% confidence interval   *p* -Value
  ---------------------------------------------------------- ------------ ------------------------- ------------
  Neonatal Composite [a](#FN190001-4){ref-type="table-fn"}   0.50         0.22--1.11                0.09
  Chorioamnionitis [b](#FN190001-5){ref-type="table-fn"}     0.75         0.43--1.31                0.31
  Endometritis [c](#FN190001-6){ref-type="table-fn"}         0.35         0.14--0.91                0.03

Adjusted for maternal age, race, maternal drug use, neonatal gender, gestational age at birth, birth weight, magnesium exposure, clindamycin exposure, and corticosteroids.

Adjusted for maternal age, race, group B strep status, and maternal smoking.

Adjusted for clindamycin exposure, drug use, race, delivery route, and chorioamnionitis.

Discussion
==========

Among women with pregnancies affected by PPROM, receiving a non- *β* -lactam and macrolide containing antibiotic regimen was associated with increased risk of endometritis. Neonates born to women who received the gold standard antibiotic regimen of a *β* -lactam and macrolide were less likely to have bronchopulmonary dysplasia but more likely to have severe necrotizing enterocolitis.

Our findings suggest improved neonatal outcomes with administration of *β* -lactam antibiotics in PPROM those are supported by previous research. The current standard of care for antibiotic administration in PPROM was established based on the results from a large, multicenter, randomized controlled trial evaluating use of ampicillin and erythromycin on a composite neonatal outcome. [@JR190001-3] In that study, a decrease in composite neonatal morbidity, respiratory distress, necrotizing enterocolitis, sepsis, pneumonia, patent ductus arteriosus, bronchopulmonary dysplasia, and hyperbilirubinemia with *β* -lactam and macrolide antibiotic administration was seen. [@JR190001-3] Our study, combined with many other studies, has demonstrated improvement in neonatal outcomes in PPROM with administration of a *β* -lactam antibiotic. [@JR190001-4] [@JR190001-5] [@JR190001-6] [@JR190001-11] However, Mercer et al [@JR190001-3] excluded women with allergy to PCN or erythromycin from their study. Thus, our study is unique in its aim to describe the effect of non- *β* -lactam antibiotic regimens in PPROM used in the setting of a PCN allergy.

Our study is furthermore unique given the finding of decreased risk of endometritis in women receiving a *β* -lactam containing antibiotic regimen. Previous studies have shown that antibiotics in general decrease maternal chorioamnionitis and pregnancy latency in the setting PPROM. [@JR190001-4] [@JR190001-7] [@JR190001-11] However, previous studies have not shown decreased rates of endometritis. [@JR190001-5] [@JR190001-6] However, other postpartum infectious morbidities have been shown to be more common among women receiving non- *β* -lactam regimens. [@JR190001-12]

The trend toward increasing severe necrotizing enterocolitis in the neonates receiving a *β* -lactam regimen in both analyses is not novel. Previous studies have demonstrated an increased risk of necrotizing enterocolitis with coamoxiclav, as well as with ampicillin. [@JR190001-13] [@JR190001-14] A plausible mechanism of action for the development of necrotizing enterocolitis in this population is alteration in the neonatal intestinal mircobiome. [@JR190001-15] Several studies have shown that maternal antepartum antibiotic administration has altered neonatal intestinal bacterial colonization. [@JR190001-16] [@JR190001-17] Their newborn\'s intestinal mircobiome may also be altered and predispose the neonate to necrotizing enterocolitis.

The participants in the non- *β* -lactam group were exposed to alternative antibiotics and it is possible exposure to these antibiotics confounds our results. One of the most common antibiotics women in the non- *β* -lactam group received was clindamycin. Formulations of this antibiotic containing the preservative benzyl alcohol have been associated with adverse neonatal outcomes related to "gasping syndrome." [@JR190001-18] [@JR190001-19] "Gasping syndrome" has been reported in premature infants exposed to clindamycin and results in multisystem organ failure and often death. [@JR190001-19] Although we cannot determine the specific formulations that neonates in out cohort received, it is possible that women in the non- *β* -lactam group suffered adverse neonatal morbidities from their antibiotic exposure that were not quantified in our study.

We recognize other limitations to our study. As a retrospective cohort study, we are inherently limited to observational data, such as, we cannot assess causation. Additionally, given we performed a secondary analysis of the BEAM trial of antenatal magnesium sulfate for the prevention of cerebral palsy, we are limited in our analysis by the data that were collected for the primary analysis. For example, we do not have data on the timing of antibiotic administration in relation to PPROM, labor, and delivery; antibiotic dosing, total doses, and frequency of dosing. Our study design of a secondary analysis also limited our sample size and a post hoc power analysis demonstrated that the study was underpowered to show a difference. We detected at 24% increase in the primary outcome in the non- *β* -lactam and macrolide group. However, based on the ratio of women in *β* -lactam and macrolide group to non- *β* -lactam and macrolide group (roughly 7:1), we would need 2,767 women in the *β* -lactam group and 415 women in the non- *β* -lactam and macrolide group to detect a difference in the primary outcome. However, our findings are hypothesis generating and suggest need for further study. Also, we did have to exclude a large number of patients for either incomplete data or administration of a *β* -lactam antibiotic without a macrolide. Finally, we were unable to compare PCNs versus cephalosporins on maternal or neonatal outcomes given they were analyzed together as *β* -lactam antibiotics.

Our study also has several strengths. First, large sample size decreases risk of type 2 error. Also, because the original data were collected from multiple centers nationwide by trained data abstractors, the data represent a diverse patient population and the results are more likely to be generalized. Finally, as there is limited data available in the literature regarding the efficacy of a non- *β* -lactam regimen on women with PPROM, this study adds information for the clinician that is applicable in daily practice.

Conclusion
==========

In conclusion, women with PPROM receiving a *β* -lactam and macrolide were less likely to suffer from endometritis. Additionally, among neonates with PPROM the administration of a *β* -lactam antibiotics did not impact composite neonatal morbidity. However, alterations in individual neonatal morbidities suggest that follow-up studies are needed to further investigate the effects of non- *β* -lactam antibiotic regimens on pregnancies affected by PPROM. Given these associations, practitioners should appropriately use cephalosporins in patients with a nonsignificant PCN allergy and should consider PCN allergy testing in all pregnant women with significant allergies to optimize maternal and neonatal outcomes in pregnancies affected by PPROM in the setting of PCN allergy.

**Conflicts of Interest** The authors report no conflicts of interest.
